10X Genomics partners with Cleveland Clinic to advance bladder cancer research

Shares of 10X Genomics rose by 3.8% after the company announced a new research partnership with Cleveland Clinic. The collaboration will focus on bladder cancer, using advanced technologies to study tumour behaviour and treatment responses. The company currently has a market value of around $4.03 billion. The partnership aims to identify biomarkers in bladder cancer using 10X Genomics' single-cell and spatial analysis platforms, including Flex Apex, Xenium, and Atera. Scientists will examine tumour specimens from patients with advanced disease to assess responses to antibody-drug conjugate therapies.

The research will explore the tumour microenvironment, immune cell infiltration, and mechanisms of therapy resistance. It will combine single-cell transcriptomic profiling, spatial gene expression analysis, and protein quantification to build a detailed clinical database.

Dr. Timothy Chan, who leads Cleveland Clinic’s Department of Cancer Sciences, called the work promising. He believes it could provide valuable insights into how major cancers respond to treatment. For 10X Genomics, the agreement aligns with its strategy to partner with leading institutions and gather evidence for future diagnostic products in oncology and other areas.

The project remains in the research phase, with no set timelines for commercialisation or revenue projections. Meanwhile, company insiders have sold $1.8 million worth of shares over the past three months, with no recorded purchases. The announcement has boosted investor confidence, reflected in the share price increase. The findings from this research could eventually support the development of new diagnostic tools. For now, the focus remains on expanding scientific understanding of bladder cancer and its treatment.